论文部分内容阅读
目的探讨急性白血病(AL)患者血清可溶性细胞间粘附分子-1(sICAM-1)、转化生长因子β1(TGF-β1)和白血病抑制因子(LIF)水平与急性白血病的病情、疗效和预后的关系。方法用酶联免疫夹心法(ELISA)测定44例急性白血病患者化疗前后血清sICAM-1、TGF-β1和LIF水平。结果与正常组比较,AL患者血清sICAM-1水平明显升高(P>0.05),TGF-β1水平明显降低(P<0.01),LIF水平有下降的趋势,但无显著性差异(P>0.05)。患者获完全缓解(CR)时,该三种细胞因子的水平又恢复正常;复发时,该三种细胞因子的水平又趋升高或降低,并接近治疗前的水平。结论sICAM-1、TGF-β1和LIF均参与了白血病的免疫发病机制。检测AL患者血清上述三种细胞因子的水平,为AL患者监测病情、评价疗效、指导临床用药及预后判断提供较为客观的指标。
Objective To investigate the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), transforming growth factor β1 (TGF-β1) and leukemia inhibitory factor (LIF) in patients with acute leukemia and the prognosis of acute leukemia relationship. Methods The levels of sICAM-1, TGF-β1 and LIF in 44 acute leukemia patients before and after chemotherapy were measured by enzyme-linked immunosorbent assay (ELISA). Results Compared with the normal group, serum sICAM-1 level was significantly increased (P> 0.05), TGF-β1 level was significantly lower (P <0.01) and LIF level was lower in AL patients (P> 0.05 ). The levels of these three cytokines returned to normal after patients had complete remission (CR); at the time of relapse, the levels of these three cytokines tended to increase or decrease again, approaching the pre-treatment levels. Conclusion sICAM-1, TGF-β1 and LIF are involved in the pathogenesis of leukemia. AL patients serum levels of these three cytokines detected for AL patients to monitor the disease, evaluate the efficacy of clinical medication and prognosis to provide more objective indicators.